Whole Genome and Exome Sequencing Global Market: Growth Projections, Key Segments, Competitive Landscape, and Future Opportunities 2024-2033

"The Business Research Company recently released a comprehensive report on the Global Whole Genome And Exome Sequencing Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.

According to The Business Research Company's, The whole genome and exome sequencing market size has grown exponentially in recent years. It will grow from $1.61 billion in 2023 to $2.02 billion in 2024 at a compound annual growth rate (CAGR) of 25.5%. Thegrowth in the historic period can be attributed to decreasing sequencing costs, rise in genetic disorders, clinical applications, genomic data repositories, advancements in bioinformatics.

The whole genome and exome sequencing market size is expected to see exponential growth in the next few years. It will grow to $4.91 billion in 2028 at a compound annual growth rate (CAGR) of 24.8%. The growth in the forecast period can be attributed to population genomics initiatives, rising demand for precision medicine, advancements in single-cell sequencing, expansion of non-invasive prenatal testing (NIPT), application in rare disease research. Major trends in the forecast period include expanded clinical adoption, rapid advancements in sequencing technologies, rise of population-scale genomic studies, integration of artificial intelligence (AI) and machine learning (ML), expanding applications in oncology.

Get The Complete Scope Of The Report @
https://www.thebusinessresearchcompany.com/report/whole-genome-and-exome-sequencing-global-market-report

Market Drivers and Trends:

The rising demand for personalized medicine is expected to propel the growth of the whole genome and exome sequencing market in the future. Personalized medicine is an approach to medical treatment that tailors healthcare decisions and interventions to the individual characteristics of each patient, considering factors such as genetics, environment, and lifestyle. Whole genome and exome sequencing is used in personalized medicine by providing a comprehensive analysis of an individual's genetic makeup, allowing for tailored healthcare decisions and interventions based on their unique genetic, environmental, and lifestyle factors. For instance, in October 2022, according to the Personalized Medicine Coalition (PMC), a US-based organization that promotes the understanding and adoption of personalized medicine, more than 75,000 genetic testing products and 300 personalized medicines are expected to be on the market in 2022. Furthermore, the Food and Drug Administration's Center for Drug Evaluation and Research (CDER) approved 37 new molecular entities (NMEs) in 2022. Further, out of the 35 therapeutic NMEs, approximately 34%, which amounts to 12 of them, are classified as personalized. Therefore, the rising demand for personalized medicine is driving the growth of the whole genome and exome sequencing market.

Major companies operating in the whole genome and exome sequencing markets are increasing their focus on developing advanced technological solutions, such as ultra-fast NGS (next-generation sequencing) analysis, to gain a competitive edge in the market. Ultra-fast NGS analysis is a technological innovation that enables the processing of next-generation sequencing (NGS) data at an exceptionally high speed, significantly reducing the time required for genomic data analysis. For instance, in January 2023, QIAGEN Digital Insights (QDI), a US-based bioinformatics company, launched the ultra-fast NGS analysis platform. This platform offers features such as processing a whole genome in 25 minutes for $1 in cloud computing costs, promoting efficiency, affordability, and scalability; its technological innovation significantly enhances genomic data analysis speed and accessibility, thus holding considerable importance in the whole genome and exome sequencing market by enabling rapid decision-making and wider adoption of personalized medicine.

Key Benefits for Stakeholders:

• Comprehensive Market Insights: Stakeholders gain access to detailed market statistics, trends, and analyses that help them understand the current and future landscape of their industry.
• Informed Decision-Making: The reports provide crucial data that support strategic decisions, reducing risks and enhancing business planning.
• Competitive Advantage: With in-depth competitor analysis and market share information, stakeholders can identify opportunities to outperform their competition.
• Tailored Solutions: The Business Research Company offers customized reports that address specific needs, ensuring stakeholders receive relevant and actionable insights.
• Global Perspective: The reports cover various regions and markets, providing a broad view that helps stakeholders expand and operate successfully on a global scale.

Ready to Dive into Something Exciting? Get Your Free Exclusive Sample of Our Research Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=13957&type=smp

Major Key Players of the Market:

Siemens AG, Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Cytiva (Danaher Corporation), Laboratory Corporation of America Holdings (Labcorp), Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., Canon Medical Systems Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V, Neusoft Corporation, BGI Genomics, Mirion Technologies (Capintec) Inc., Novogene Co., Oxford Nanopore Technologies Inc., LANDAUER, Pacific Biosciences of California Inc., Digirad Corporation, Berthold Technologies GmbH & Co.KG, GENEWIZ Inc., Incom Inc., Lucerno Dynamics LLC, Absolute Imaging Inc., Mediso Ltd., Ashby Gorman Baker Ltd., DDD-Diagnostic AS, SurgicEye GmbH, CMR Naviscan

Whole Genome And Exome Sequencing Market 2024 Key Insights:

• The whole genome and exome sequencing market is expected to grow to $4.91 billion in 2028 at a compound annual growth rate (CAGR) of 24.8%.
• The Surge In Demand For Personalized Medicine Boosts The Whole Genome And Exome Sequencing Market
• Key Player Introducing Ultra-Fast NGS Solutions to Transform Whole Genome and Exome Sequencing Markets
• North America was the largest region in the whole genome and exome sequencing market in 2023

We Offer Customized Report, Click @
https://www.thebusinessresearchcompany.com/Customise?id=13957&type=smp

Contact Us:

The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.